Airsculpt Technologies (AIRS) AI Stock Analysis

• Market Cap: $214.78M
• Dividend Yield: N/A
• Average Volume (3M): 1.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.82
• Revenue Growth: -16.54%
• EPS Growth: -119.56%
• Country: US
• Employees: 389
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.04
• Shares Outstanding: 62,436,670
• 10 Day Avg. Volume: 916,257
• 30 Day Avg. Volume: 1,544,323
• PEG Ratio: -0.47
• Price to Book (P/B): 3.78
• Price to Sales (P/S): 1.66
• P/FCF Ratio: -112.69
• Enterprise Value/Market Cap: 2.71
• Enterprise Value/Revenue: 3.69
• Enterprise Value/Gross Profit: 5.77
• Enterprise Value/Ebitda: 357.57
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.11
• Revenue Forecast (FY): $155.66M

• Rating: 43 Neutral
• Price Target: $3.50 ▼(-1.96% Downside)

Airsculpt Technologies faces significant financial and operational challenges, with declining revenues and profitability pressures being the most impactful factors. The bearish technical indicators and negative valuation metrics further weigh down the stock's attractiveness. While strategic initiatives in the GLP-1 market offer potential growth opportunities, the current transitional phase and operational challenges limit the overall score.

Positive Factors

Strategic Expansion into GLP-1 Market

The expansion into the GLP-1 market with new services like skin tightening represents a significant growth opportunity, leveraging the 38% annual growth in GLP-1 prescriptions.

Debt Reduction Achievements

Reducing debt enhances financial flexibility, improving the capital structure and positioning the company for future growth and stability.

Improvements in Cost Management

Effective cost management and savings are expected to expand operating margins, supporting long-term profitability and operational efficiency.

Negative Factors

Revenue and Case Decline

Significant revenue and case declines indicate challenges in maintaining market position and could impact long-term financial health if not addressed.

Closure of Unprofitable London Center

Closing unprofitable centers reflects operational challenges and may limit international expansion, impacting growth potential.

Adjusted EBITDA Decline

Declining EBITDA and margins suggest profitability pressures, which could hinder reinvestment and strategic initiatives if not reversed.

Airsculpt Technologies Business Overview & Revenue Model

Company Description

Airsculpt Technologies (AIRS) is an innovative company that specializes in advanced surgical and non-surgical body contouring procedures. Operating primarily in the healthcare and aesthetics sectors, Airsculpt Technologies offers proprietary technologies and services designed to provide patients with minimally invasive options for body sculpting and fat removal. The company's core product line includes its patented AirSculpt® procedure, which utilizes a unique method to remove unwanted fat while ensuring minimal downtime and optimal results.

How the Company Makes Money

Airsculpt Technologies generates revenue primarily through its surgical and non-surgical body contouring procedures. The company charges patients for each procedure performed, which includes the cost of the technology used, medical staff, and facility fees. Additionally, Airsculpt Technologies may earn income through partnerships with medical practitioners and clinics that offer its services, as well as through training and support programs for those practitioners. The company could also explore potential revenue from licensing its proprietary technology to third-party providers, thereby expanding its market reach and enhancing its earnings.

Airsculpt Technologies Financial Statement Overview

Summary

Airsculpt Technologies is experiencing financial challenges, with declining revenue and profitability pressures. While there are improvements in leverage and free cash flow growth, the company struggles with negative margins and cash flow inefficiencies. Continued focus on cost management and cash flow generation is essential for future stability.

Income Statement

Airsculpt Technologies has faced declining revenue growth, with a negative growth rate in the TTM period. The company has struggled with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin has significantly decreased from previous years, indicating pressure on cost management.

Balance Sheet

The company's debt-to-equity ratio has improved in the TTM period, suggesting better leverage management compared to previous years. However, the return on equity remains negative, indicating challenges in generating returns for shareholders. The equity ratio is stable, reflecting a balanced asset structure.

Cash Flow

Airsculpt Technologies has shown improvement in free cash flow growth in the TTM period, but the free cash flow remains negative, which is a concern. The operating cash flow to net income ratio is low, indicating inefficiencies in converting income into cash. The free cash flow to net income ratio is also negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	157.55M	180.35M	195.92M	168.79M	133.31M	62.77M
Gross Profit	100.79M	108.97M	121.91M	110.51M	88.78M	39.30M
EBITDA	1.63M	10.07M	19.74M	4.59M	22.36M	15.67M
Net Income	-17.98M	-8.25M	-4.48M	-14.68M	10.55M	7.58M
Balance Sheet
Total Assets	185.92M	210.00M	204.02M	200.76M	200.55M	179.61M
Cash, Cash Equivalents and Short-Term Investments	5.41M	8.23M	10.26M	9.62M	25.35M	10.38M
Total Debt	84.21M	105.05M	99.67M	107.65M	100.58M	49.77M
Total Liabilities	103.81M	130.71M	120.03M	129.99M	117.03M	55.93M
Stockholders Equity	82.11M	79.29M	83.99M	70.77M	83.53M	123.68M
Cash Flow
Free Cash Flow	2.47M	-2.66M	14.04M	11.53M	19.52M	10.27M
Operating Cash Flow	8.34M	11.35M	23.96M	24.45M	26.63M	13.96M
Investing Cash Flow	-5.87M	-14.01M	-9.92M	-12.92M	-7.12M	-3.69M
Financing Cash Flow	-3.03M	630.00K	-13.39M	-27.26M	-4.55M	-5.02M

Airsculpt Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIRS, the sentiment is Negative. The current price of 3.57 is below the 20-day moving average (MA) of 4.69, below the 50-day MA of 7.50, and below the 200-day MA of 5.24, indicating a bearish trend. The MACD of -1.34 indicates Positive momentum. The RSI at 28.16 is Positive, neither overbought nor oversold. The STOCH value of 23.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIRS.

Airsculpt Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	72 Outperform	$2.13B	21.16	9.94%	1.82%	23.74%	-18.99%
HCSG	72 Outperform	$1.32B	34.77	8.07%	―	6.26%	-19.33%
CYH	56 Neutral	$502.83M	1.50	―	―	0.74%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMN	50 Neutral	$636.52M	―	-35.90%	―	-11.42%	-617.31%
CCRN	46 Neutral	$394.76M	-46.54	-3.76%	―	-22.14%	-787.87%
AIRS	43 Neutral	$214.78M	―	-21.85%	―	-16.54%	-119.56%

Airsculpt Technologies Corporate Events

AirSculpt Technologies Appoints Mike Doyle as Chairman

On November 14, 2025, AirSculpt Technologies appointed Mike Doyle as the Non-Executive Chairman of its Board of Directors. With over 30 years of leadership experience in the multi-center healthcare sector, Doyle’s appointment is expected to guide AirSculpt in its next phase of transformation, leveraging his expertise in building successful multi-site healthcare organizations. This strategic move aims to capture new market opportunities and create value for stakeholders.

The most recent analyst rating on (AIRS) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Airsculpt Technologies stock, see the AIRS Stock Forecast page.

AirSculpt Technologies Navigates Transition Amid Revenue Declines

AirSculpt Technologies, Inc. recently held its earnings call, revealing a mixed sentiment. While the company is optimistic about growth opportunities in the GLP-1 market and has made strides in financial discipline, it faces significant revenue declines and operational challenges, indicating a transitional phase.

AirSculpt Technologies Reports Q3 2025 Earnings

AirSculpt Technologies, Inc. is a national provider of premium body contouring procedures, specializing in minimally invasive treatments that optimize comfort and precision in the aesthetics industry. In its third quarter fiscal 2025 earnings report, AirSculpt Technologies announced a decline in revenue and case volume, attributing the decrease to timing rather than a negative business trajectory. The company reported a third-quarter revenue of $35 million, a 17.8% decrease from the previous year, and a net loss of $9.5 million, compared to a $6 million loss in the same period last year. Despite these setbacks, AirSculpt has made progress in debt reduction, having decreased its debt by $18 million and maintaining a positive cash flow year-to-date. The company also announced the appointment of Michael Arthur as the new Chief Financial Officer, effective January 2026, bringing in his experience to navigate growth and complexity. Looking ahead, AirSculpt remains optimistic about its strategic positioning in the aesthetics market and anticipates an improvement in same-store sales trends and EBITDA margin expansion in the coming quarters.

AirSculpt Technologies Appoints New Chief Financial Officer

AirSculpt Technologies announced the appointment of Michael Arthur as Chief Financial Officer, effective January 5, 2026. Arthur, a seasoned executive with experience in public market finance, is expected to enhance the company’s leadership team. The company reported a decline in third-quarter 2025 revenue and case volume compared to the previous year, attributing the revenue drop to timing issues rather than business trajectory. Despite the decline, AirSculpt remains confident in its strategy, focusing on growth opportunities and debt reduction, and anticipates improved sales trends and EBITDA margin expansion in the fourth quarter.

The most recent analyst rating on (AIRS) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Airsculpt Technologies stock, see the AIRS Stock Forecast page.